Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for 'vertical' and 'lateral' combination strategies

Ricciardi, Maria; Scerpa, Maria; Bergamo, Paola; Ciuffreda, Ludovica; Petrucci, Maria; Chiaretti, Sabina; Tavolaro, Simona; Mascolo, Maria; Abrams, Stephen; Steelman, Linda; Tsao, Twee; Marchetti, Antonio; Konopleva, Marina; Bufalo, Donatella; Cognetti, Francesco; Foà, Robin; Andreeff, Michael; McCubrey, James; Tafuri, Agostino; Milella, Michele
October 2012
Journal of Molecular Medicine;Oct2012, Vol. 90 Issue 10, p1133
Academic Journal
In hematological malignancies, constitutive activation of the RAF/MEK/ERK pathway is frequently observed, conveys a poor prognosis, and constitutes a promising target for therapeutic intervention. Here, we investigated the molecular and functional effects of pharmacological MEK inhibition in cell line models of acute myeloid leukemia (AML) and freshly isolated primary AML samples. The small-molecule, ATP-non-competitive, MEK inhibitor PD0325901 markedly inhibited ERK phosphorylation and growth of several AML cell lines and approximately 70 % of primary AML samples. Growth inhibition was due to G-phase arrest and induction of apoptosis. Transformation by constitutively active upstream pathway elements (HRAS, RAF-1, and MEK) rendered FDC-P1 cells exquisitely prone to PD0325901-induced apoptosis. Gene and protein expression profiling revealed a selective effect of PD0325901 on ERK phosphorylation and compensatory upregulation of the RAF/MEK and AKT/p70 kinase modules, potentially mediating resistance to drug-induced growth inhibition. Consequently, in appropriate cellular contexts, both 'vertical' (i.e., inhibition of RAF and MEK along the MAPK pathway) and 'lateral' (i.e., simultaneous inhibition of the MEK/ERK and mTOR pathways) combination strategies may result in synergistic anti-leukemic effects. Overall, MEK inhibition exerts potent growth inhibitory and proapoptotic activity in preclinical models of AML, particularly in combination with other pathway inhibitors. Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more effective targeted strategies for the treatment of AML.


Related Articles

  • Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Zhang, W.; Konopleva, M.; Ruvolo, V. R.; McQueen, T.; Evans, R. L.; Bornmann, W. G.; McCubrey, J.; Cortes, J.; Andreeff, M. // Leukemia (08876924);Apr2008, Vol. 22 Issue 4, p808 

    Raf/MEK/Erk signaling is activated in the majority of acute myeloid leukemias (AMLs), providing rationale for targeting this pathway with therapeutic intent. We investigated growth-inhibitory and proapoptotic effects of sorafenib in AML. Our studies demonstrated that sorafenib significantly...

  • Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Pelish, Henry E.; Liau, Brian B.; Nitulescu, Ioana I.; Tangpeerachaikul, Anupong; Poss, Zachary C.; Da Silva, Diogo H.; Caruso, Brittany T.; Arefolov, Alexander; Fadeyi, Olugbeminiyi; Christie, Amanda L.; Du, Karrie; Banka, Deepti; Schneider, Elisabeth V.; Jestel, Anja; Zou, Ge; Si, Chong; Ebmeier, Christopher C.; Bronson, Roderick T.; Krivtsov, Andrei V.; Myers, Andrew G. // Nature;10/8/2015, Vol. 526 Issue 7572, p273 

    Super-enhancers (SEs), which are composed of large clusters of enhancers densely loaded with the Mediator complex, transcription factors and chromatin regulators, drive high expression of genes implicated in cell identity and disease, such as lineage-controlling transcription factors and...

  • Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. Zebisch, A; Wölfler, A; Fried, I; Wolf, O; Lind, K; Bodner, C; Haller, M; Drasche, A; Pirkebner, D; Matallanas, D; Rath, O; Blyth, K; Delwel, R; Taskesen, E; Quehenberger, F; Kolch, W; Troppmair, J; Sill, H // Leukemia (08876924);Aug2012, Vol. 26 Issue 8, p1842 

    RAF kinase inhibitor protein (RKIP) is a negative regulator of the RAS-mitogen-activated protein kinase/extracellular signal-regulated kinase signaling cascade. We investigated its role in acute myeloid leukemia (AML), an aggressive malignancy arising from hematopoietic stem and progenitor cells...

  • Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Ruvolo, P P; Qui, Y H; Coombes, K R; Zhang, N; Ruvolo, V R; Borthakur, G; Konopleva, M; Andreeff, M; Kornblau, S M // Leukemia (08876924);Nov2011, Vol. 25 Issue 11, p1711 

    The regulation of protein kinase B (AKT) is a dynamic process that depends on the balance between phosphorylation by upstream kinases for activation and inactivation by dephosphorylation by protein phosphatases. Phosphorylated AKT is commonly found in acute myeloid leukemia (AML) and confers an...

  • Notch signaling maintains proliferation and survival of the HL60 human promyelocytic leukemia cell line and promotes the phosphorylation of the Rb protein. Guo-Hui Li; Yu-Zhen Fan; Xiao-Wei Liu; Bing-Fang Zhang; Dan-Dan Yin; Fei He; Si-Yong Huang; Zhi-Jie Kang; Heng Xu; Qiang Liu; Yan-Lan Wu; Xiao-Li Niu; Li Zhang; Li Liu; Miao-Wang Hao; Hua Han; Ying-Min Liang // Molecular & Cellular Biochemistry;Jul2010, Vol. 340 Issue 1/2, p7 

    The Notch signaling pathway has been implicated in the development of several leukemia and lymphoma. In order to investigate the relationship between Notch signaling and acute myeloid leukemia (AML), in this study, we expressed a recombinant Notch ligand protein, the DSL domain of the human...

  • Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Lee, D W; Futami, M; Carroll, M; Feng, Y; Wang, Z; Fernandez, M; Whichard, Z; Chen, Y; Kornblau, S; Shpall, E J; Bueso-Ramos, C E; Corey, S J // Oncogene;9/13/2012, Vol. 31 Issue 37, p4085 

    The myelodysplastic syndromes (MDSs) comprise a group of disorders characterized by multistage progression from cytopenias to acute myeloid leukemia (AML). They display exaggerated apoptosis in early stages, but lose this behavior during evolution to AML. The molecular basis for loss of...

  • Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Zhou, J.; Pan, M.; Xie, Z.; Loh, S.-L.; Bi, C.; Tai, Y.-C.; Lilly, M.; Lim, Y.-P.; Han, J.-H.; Glaser, K. B.; Albert, D. H.; Davidsen, S. K.; Chen, C.-S. // Leukemia (08876924);Jan2008, Vol. 22 Issue 1, p138 

    Internal tandem duplications (ITDs) of fms-like tyrosine kinase 3 (FLT3) receptor play an important role in the pathogenesis of acute myeloid leukemia (AML) and represent an attractive therapeutic target. ABT-869 has demonstrated potent effects in AML cells with FLT3-ITDs. Here, we provide...

  • Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Lee-Sherick, A B; Eisenman, K M; Sather, S; McGranahan, A; Armistead, P M; McGary, C S; Hunsucker, S A; Schlegel, J; Martinson, H; Cannon, C; Keating, A K; Earp, H S; Liang, X; DeRyckere, D; Graham, D K // Oncogene;11/14/2013, Vol. 32 Issue 46, p5359 

    Acute myeloid leukemia (AML) continues to be extremely difficult to treat successfully, and the unacceptably low overall survival rates mandate that we assess new potential therapies to ameliorate poor clinical response to conventional therapy. Abnormal tyrosine kinase activation in AML has been...

  • The Histone Code and Treatments for Acute Myeloid Leukemia. Godley, Lucy A.; Le Beau, Michelle M. // New England Journal of Medicine;3/8/2012, Vol. 366 Issue 10, p960 

    The article focuses on the histone code and treatments for acute myeloid leukemia. Several short hairpin RNA designed to reduce the expression of BRD4, a gene encoding a protein that recognizes acetylated histones, were found to inhibit the growth of an MLL-associated acute myeloid leukemia and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics